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Abstract
Rationale The novel opioid receptor antagonist ,
GSK1421498, has been shown to attenuate reward-driven
compulsive behaviours, such as stimulant drug seeking or
binge eating, in animals and humans. Here, we report new
data on the receptor pharmacology of GSK121498, in com-
parison to naltrexone, naloxone, 6-β-naltrexol and
nalmefene.
Objectives To determine whether the novel opioid antagonist,
GSK1521498, is an orthosteric or allosteric antagonist at the μ
opioid receptor (MOPr) and whether it has neutral antagonist
or inverse agonist properties.
Methods A combination of radioligand binding assays and
[35S]GTPγS binding assays was employed.
Results GSK1521498 completely displaced [3H]naloxone
binding to MOPr and did not alter the rate of [3H]naloxone
dissociation fromMOPr observations compatible with it bind-
ing to the orthosteric site on MOPr. GSK1521498 exhibited
inverse agonismwhenMOPrwas overexpressed but not when
the level of MOPr expression was low. In parallel studies
under conditions of high receptor expression density, nalox-
one, naltrexone, 6-β-naltrexol and nalmefene exhibited partial
agonism, not inverse agonism as has been reported previously
for naloxone and naltrexone. In brain tissue from mice receiv-
ing a prolonged morphine pre-treatment, GSK1521498 exhib-
ited slight inverse agonism.
Conclusions Differences between GSK1521498 and naltrex-
one in their effects on compulsive reward seeking are arguably
linked to the more selective and complete MOPr antagonism
of GSK1521498 versus the partial MOPr agonism of naltrex-
one. GSK1521498 is also pharmacologically differentiated by
its inverse agonist efficacy at high levels of MOPr expression,
but this may be less likely to contribute to behavioural differ-
entiation at patho-physiological levels of expression.





phate (1:1)) is a novel opioid receptor antagonist under clinical
development for disorders of compulsive consumption (Ignar
et al. 2011; Nathan et al. 2012a, b). Behavioural studies in
rodent models of compulsive consumption have demonstrated
that GSK1521498 can significantly, and dose dependently,
attenuate compulsive searching for cocaine, heroin or choco-
late rewards and compulsive consumption of heroin or food
rewards (Giuliano et al. 2012, 2013). GSK1521498 could be
behaviourally differentiated from naltrexone in these experi-
ments: GSK1521498 in the dose range 0.1–3 mg/kg had
greater effects than equivalent doses of naltrexone on cocaine
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seeking, heroin seeking and heroin consumption. For exam-
ple, GSK1421598 3 mg/kg was associated with a 2.5-fold
greater reduction in cocaine seeking and a 5.5-fold greater
reduction in heroin seeking, compared to naltrexone 3 mg/kg
(Giuliano et al. 2013).
Here, we report a detailed characterization of the receptor
pharmacology of GSK1521498 compared to naltrexone, and
its principal metabolite 6-β-naltrexol, in cell lines and in brain
tissue from morphine-treated animals. We hypothesized that
the behavioural differences between GSK1521498 and nal-
trexone observed previously could be related to pharmacolog-
ical differences in μ-opioid receptor (MOPr) selectivity or
efficacy.
In an initial study of its receptor pharmacology,
GSK1521498 was reported to be selective for recombinant
humanMOPr over κ (KOPr) and δ (DOPr) (Ignar et al. 2011).
Furthermore, in cell membranes from CHO-Gam E1A cells
virally expressing high levels of recombinant receptor,
GSK1521498 exhibited inverse agonism, at MOPr, KOPr
and DOPr. In contrast, the classical opioid antagonist naltrex-
one demonstrated neutral antagonist/partial agonist activity at
MOPr and KOPr and neutral antagonist activity at DOPr
(Ignar et al. 2011).
Under certain experimental conditions, MOPrs have been
reported to exhibit constitutive activity which can be inhibited
by some opioid antagonists indicating that they may also have
inverse agonist activity (Burford et al. 2000; Liu et al. 2001;
Wang et al. 2001, 2004, 2007). For example, β-
chlornaltrexamine (βCNA) was reported to reduce the basal
level of GTPγS binding in membranes prepared from either
mouse brain or cell lines expressing recombinant MOPr
(Wang et al. 2004). While the inverse agonism induced by
βCNAwas apparent in brain membranes prepared from con-
trol mice, it was enhanced in membranes prepared from mice
pretreated with morphine for 1 or 3 days when constitutive
activity of MOPr was reported to be increased. Furthermore,
while naltrexone and naloxone exhibited neutral antagonist
activity in control membrane preparations, these drugs also
exhibited inverse agonist effects in membranes from
morphine-pre-treated cells (Wang et al. 2001, 2007) or mem-
branes prepared from morphine-treated mice brains (Wang
et al. 2004). The principal (active) metabolite of naltrexone,
6-β-naltrexol, was reported to act as a neutral antagonist
irrespective of the conditions of the experiment (Wang et al.
2001, 2004, 2007).
Other studies, however, have failed to observe inverse
agonist activity with MOPr antagonists and have observed
either neutral antagonism or weak partial agonism (for review
see Connor and Traynor 2010). For example, in different
studies, naloxone has been reported to possess positive
(Burford et al. 2000; Liu and Prather 2001; Wang et al.
2007), neutral (Brillet et al. 2003; Divin et al. 2009) or
negative intrinsic activity (Liu and Prather 2001; Sally et al.
2010; Wang et al. 2004, 2007). The issue of whether MOPrs
exhibit constitutive activity and thus whether some antago-
nists exhibit inverse agonism is still controversial (Connor and
Traynor 2010; Williams et al. 2013).
The objective of the present study was to characterize the
effects of GSK1521498 at opioid receptors in vitro and to
compare them with several established opioid antagonists that
have previously been reported to have neutral antagonist or
inverse agonist activity: naltrexone, 6-β-naltrexol, nalmefene,
βCNA. We confirmed that GSK1521498 showed selectivity
for MOPr over the other opioid receptors and have addition-
ally demonstrated that it binds to the orthosteric binding site
on MOPr. We demonstrated that GSK1521498 could more
completely block MOPr transmission than naltrexone, which
had partial agonist efficacy. In contrast, we found further
evidence that GSK1521498 had some inverse agonist activity,
but this was observed using highly expressed recombinant
MOPr, or endogenous MOPr from mice pre-treated with the
highest dose of morphine, but not endogenous MOPr from
control mice or mice pre-treated with lower doses of mor-
phine. We were unable to observe inverse agonist activity




(i) MOPr-, DOPr-, KOPr- and ORL1 (NOPr-) Chinese ham-
ster ovary (CHO) cells
CHO cells stably expressing human MOPr, DOPr,
KOPr and NOPr, respectively, were grown to ~90 %
confluency, washed with PBS prior to being detached
with Versene or trypsin and collected by centrifugation
(330 g, 5 min, 4 °C). The cell pellets were rinsed once in
PBS and homogenized in ten volumes (w/v) of membrane
preparation buffer (50 mM HEPES, 0.1 mM leupeptin,
1 mMEDTA, 0.1 mM Pefabloc and pepstatin A pH=7.4)
using an Ultra-Turrax homogenizer (2×15-s bursts). The
homogenates were then centrifuged at 48,000×g for
20 min at 4 °C, and the pellets were washed once more
in membrane preparation buffer and re-centrifuged as
before. The final pellets were resuspended in five vol-
umes of membrane preparation buffer and frozen at
−80 °C until use. Protein concentration was determined
by the Bio-Rad Protein assay using bovine serum albu-
min (BSA) as the standard.
(ii) MOPr-human embryonic kidney (HEK) 293 cells
HEK293 cells stably expressing human MOPr (ap-
proximately 1,600 fmol/mg protein) were grown to
~90 % confluency then gently washed twice with 2-ml
ice-cold hypotonic lifting buffer (10 mMHEPES, 0.9 %
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w/v NaCl, 0.2 %w/v EDTA, pH 7.4). Cells were then
removed from the bottom of the dish using an Iwaki cell
scraper and suspended in 2 ml of ice-cold lifting buffer.
The cells were pelleted by centrifugation (377×g,
10 min, 4 °C) before discarding the supernatant
and resuspending in 2 ml of ice-cold wash buffer
1 (10 mM HEPES, 10 mM EDTA, pH 7.4). The
centrifugation step was then repeated and the wash
cycle repeated twice more. The washed cell sus-
pension was then homogenised using 4×5-s bursts
with an Ultra-Turrax homogeniser. The homoge-
nate was then centrifuged (48,000×g, 30 min,
4 °C) before the supernatant was discarded and
pellet was resuspended in 2 ml of ice-cold wash
buffer 1. The centrifugation was then repeated,
before resuspension of the pellet in 3 ml of ice-
cold wash buffer 2 (10 mM HEPES, 0.1 mM
EDTA, pH 7.4) at protein concentrations of 2–
5 mg/ml. Aliquots of membrane protein were
stored at −80 °C until use.
(iii) Mouse brain
All animal experiments were carried out in accor-
dance with the UKAnimals (Scientific Procedures) Act,
1986, and associated guidelines. Male CD1 mice (25–
30 g) were obtained from Banting and Kingman (UK)
and housed at the University of Bristol’s animal facility.
They had access to food and water ad libitum. Four
groups of mice were used.
1. Naive mice—untreated
2. Acute morphine-pretreated mice received 100 mg/kg
morphine subcutaneous (sc) 4 h before sacrifice
3. Moderate morphine-pretreated mice received sc in-
jections of morphine at 8-h intervals for 3 days (day
1—3×30 mg/kg, day 2—3×60 mg/kg, day 3—3×
100 mg/kg). Animals were sacrificed 12 h later on
day 4.
4. Severe morphine-pretreated mice were implanted sc
under isoflurane anaesthesia with a morphine pellet
containing 75 mg morphine. Animals were sacrificed
3 days after pellet implantation. It has been estimated
that this treatment results in brain morphine levels that
peak around 600 ng/g tissue and remain above
200 ng/g tissue over the period of administration
(Patrick et al. 1975)
The categorization of morphine pre-treatment is as de-
scribed by Raehal et al. (2005).
Brain membranes were prepared as described by Wang
et al. (2004). Animals were killed by cervical dislocation
and their brains removed, placed in Eppendorf tubes and
frozen in liquid nitrogen. The tubes were then stored at
−80 °C until used. To prepare membranes, brains were
homogenized (4 × 5-s bursts using an Ultra-Turrax
homogeniser) in buffer containing 50 mM Tris-HCl, pH 7.5,
100 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol (DTT),
1 mMMgCl2 and 0.25M sucrose at 4 °C and then centrifuged
at 27,000×g for 10 min (4 °C). The resulting pellet was
resuspended in homogenizing buffer and centrifuged twice
more (as described above), before the final pellet was
resuspended in homogenizing buffer and stored in ali-
quots at −80 °C. The protein concentration of the ali-
quots was determined to be naïve 2.41 mg/ml, morphine
acute 2.35 mg/ml, morphine moderate 2.22 mg/ml and
morphine severe 2.21 mg/ml.
[35S]GTPγS binding assay
[35S]GTPγS binding studies in CHO cell membranes from
MOPr overexpressing cells were performed in 384-well for-
mat using scintillation proximity assays (SPAs).MOPr, DOPr,
KOPr and NOP membranes were diluted to 10, 20, 30 and
2 μg/ml, respectively, in assay buffer (20 mMHEPES, 10mM
MgCl2, 100 mM NaCl, pH 7.4) supplemented with 5 μM
GDP, 30 μg/ml saponin, 0.01 % Pluronic F1275, 5 mg/ml
wheat germ agglutinin-polystyrene imaging beads
(PerkinElmer) and 0.5 nM [35S]GTPγS (1,250 Ci/mmol).
The reaction mixtures were incubated for 2 h at 25 °C with
different concentrations of test compound or vehicle (DMSO)
in the absence (agonist mode) or presence (antagonist mode)
of a sub-maximal concentration of agonist (Met-Enk,
dynorphin A and nociceptin for MOPr/DOPr, KOPr and
NOPr, respectively). The final assay volume was 20 μl for
MOPr and NOP and 40 μl for DOPr and KOPr. Basal
[35S]GTPγS binding was determined in the absence of com-
pounds. Bound [35S]GTPγS was determined by scintillation
counting on a ViewLux microplate imager (Wallac 1430,
PerkinElmer).
To study potential inverse agonism at MOPr in
mouse brain membranes and CHO cells expressing low
levels of MOPr, we used conditions identical to those of
Wang et al. (2004), using an assay buffer containing
50 mM Tris-HCl pH 7.5, 100 mM NaCl, 4 mM MgCl2,
1 mM DTT, 10 μM GDP, 1 mM EDTA and 0.1 %
BSA. Brain membranes (10 μg/tube) were incubated
with assay buffer as well as drug and 0.1 nM
[35S]GTPγS (1,250 Ci/mmol) at 30 °C for 30 min be-
fore rapid filtration on a Brandel Cell Harvester using
Whatman GF/B filters and scintillation counting.
Radioligand binding assay
Membranes were prepared from MOPr-HEK 293 cells as
described above. For competition binding experiments, com-
peting ligands were prepared in increasing concentrations in
HBSS/20 mM HEPES/pH 7.4, in LP4 tubes containing
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10 μg of protein per well. Then, 4 nM [3H]naloxone was
added to each tube, and binding reactions were left to
incubate at 22 °C for 2 h with agitation. In parallel
samples, non-specific binding was determined with
1 μM etorphine. Both total binding and non-specific
b inding curves were per fo rmed in dup l ica te .
Membranes were then harvested onto filter paper discs
moistened with ice-cold wash buffer: HEPES 20 mM,
pH7.4. Each disc of filter paper was placed in a scin-
tillation vial and 3-ml Emulsifier-Safe scintillation fluid
added. Samples were left for 3 h before reading in a
scintillation counter. For competition dissociation bind-
ing experiments, 10 μg of protein plus 4 nM
[3H]naloxone was added to each tube, and binding
reactions were left to incubate at 22 °C for 2 h with
agitation. Then, 3 ml of quenching solution containing
unlabelled naloxone (1 μM) to prevent rebinding of
[ 3H ]na l oxone t o t h e o r t ho s t e r i c s i t e ± e i t h e r
GSK1521498 (1 μM), 6-β-naltrexol (1 μM) or naltrex-
one (1 μM) was added and the incubation continued for
various times from 0 s to 15 min. In parallel samples,
non-specific binding was determined with 1 μM
etorphine. Membranes were then harvested and radioac-




1,250 Ci/mmol) and [3H]naloxone (1 mCi/ml) were from
PerkinElmer. Drugs and reagents were obtained from the
following sources: β-chlornaltrexamine dihydrochloride
(β-CNA), methionine enkephalin acetate salt hydrate
(Met-Enk), dynorphin A (porcine), naltrexone, 6-β-
naltrexol, nalmefene and materials for membrane prepa-
ration (all from Sigma); etorphine hydrochloride and
morphine base pellets (from RTI); morphine hydrochlo-
ride (from Macfarlan Smith); nociceptin and naloxone
hydrochloride (from Tocris).
Data analysis and statistics
Concentration-response curves and ligand-displacement
curves were determined by fitting data from individual
experiments to sigmoidal concentration-response curves
with variable slope in Graphpad Prism 5.0, with fpKi
(pKi measured in a functional assay) and pKi (measured
in a radioligand binding assay) and S.E.M. calculated
using individual values from each experiment. The dis-
sociation of [3H]naloxone in the absence and presence
of other ligands was fitted to a single exponential decay
in Graphpad Prism 4.0. Data were analyzed using a
Student’s t test, ANOVA or one-way ANOVA with
Bonferroni post-test as appropriate.
Results
Opioid receptor selectivity
To determine the antagonist selectivity of GSK1521498 for
opioid receptors, we examined its ability to antagonize
agonist-activated [35S]GTPγS binding in cell membranes pre-
pared from CHO cells overexpressing either MOPr, DOPr,
KOPr or NOPr and compared it to four other opioid antago-
nists, naloxone, naltrexone 6-β-naltrexol and nalmefene. The
agonists used to stimulate each opioid receptor subtype were
Met-Enk (MOPr and DOPr), dynorphin (KOPr) and
nociceptin (NOPr). GSK1521498 showed antagonist activity
at all four opioid receptors and was the most potent antagonist
at MOPr (Fig. 1 and Table 1). It had 14-fold selectivity for
MOPr over DOPr and KOPr and 100-fold selectivity for
MOPr over NOPr. When administered alone, GSK1521498
did not show agonist activity at any of the opioid receptors at
concentrations up to 100 μM (see Fig. 3 for MOPr; data not
shown for KOPr and DOPr). It did exhibit slight inverse
agonism at MOPr (see below and Fig. 3) but not at any of
the other opioid receptors.
Fig. 1 Inhibition of Met-Enk-stimulated [35S]GTPγS binding to mem-
branes prepared from CHO cells overexpressing MOPr. Concentration-
response curve for GSK1521498 (black square), naloxone (black circle),
naltrexone (white circle), 6β-naltrexol (black up-pointing triangle) and
nalmefene (white square) for inhibiting 10-nM Met-Enk-stimulated
[35S]GTPγS binding in CHO cells expressing MOPr. Mean data are
expressed as percentage of the stimulation produced by Met-Enk and
are from three experiments each performed in duplicate. For each curve,
the maximum was constrained to 100 % and the slope to unity
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In contrast, naloxone, naltrexone, 6-β-naltrexol and
nalmefene did not produce complete inhibition of the agonist
responses at MOPr (Fig. 1), which is compatible with their
partial agonist activity in this expression system (see below
and Fig. 3).
Binding to the MOPr
Radioligand-binding studies can provide important informa-
tion on how a ligand interacts with a receptor, not only the
affinity of binding but also whether it binds at the orthosteric
site or at an allosteric site on the receptor.
Competition displacement binding curves were construct-
ed for the displacement of 3H-naloxone binding by
GSK1521498, naltrexone and 6-β-naltrexol from MOPrs
expressed in HEK293 cells. All three compounds displaced
specific 3H-naloxone binding in a concentration-dependent
manner with the maximum displacement being 100 % for
each (Fig. 2a–c). pKi values calculated using the Cheng-
Prussoff equation are given in Table 2. The order of affinity
of binding to human MOPr was GSK1521498>naltrexone=
6-β-naltrexol.
To further examine whether GSK1521498 might act
at an allosteric site on MOPr to alter binding at the
orthosteric ligand binding site, we determined whether it
altered the rate of 3H-naloxone dissociation from
MOPrs. Non-radioactive naloxone was added to prevent
rebinding of 3H-naloxone once it had dissociated from
MOPr. The dissociation of 3H-naloxone from MOPr at
22 °C could be fitted by a single exponential (Fig. 2d).
The t1/2 for dissociation was 0.59 min (95 % confidence
limits 0.52–0.68; n=7). In the presence of GSK1521498
(1 μM), the rate of 3H-naloxone dissociation was un-
changed (Fig. 2d). Similarly, the rate of 3H-naloxone
dissociation was unchanged in the presence of naltrex-
one (1 μM) or 6-β-naltrexol (1 μM) (Fig. 2d). These
data are compatible with GSK1521498, naltrexone and
6-β-naltrexol binding to the orthosteric site on MOPr to
which naloxone binds.
Inverse agonism at MOPr
In GTPγS binding studies on CHO cell membranes express-
ing recombinant MOPrs, we observed that GSK1521498 pro-
duced a slight inhibition (up to 18 %) of basal [35S]GTPγS
binding (Fig. 3). This would indicate some inverse agonist
activity of GSK1521498. In contrast, naltrexone, naloxone,
6-β-naltrexol and nalmefene enhanced basal [35S]GTPγS
binding (by 40, 20, 30 and 20 %, respectively) indicating
partial agonist activity, not inverse agonist activity of these
compounds (Fig. 3a). The partial agonist activity of these
antagonists would explain why they did not completely inhibit
the agonist actions of Met-Enk on MOPr shown in Fig. 1.
In these recombinant MOPr-GTPγS binding assays, we
used highly overexpressed MOPrs in CHO cell membranes
(Bmax 14,500 fmol/mg protein). The overexpression of
MOPr is evidenced by the high potency of Met-Enk to stim-
ulate [35S]GTPγS binding (EC50 0.6 nM, 95 % confidence
limits 0.4 to 0.8 nM): In rat brain neurons, the EC50 for Met-
Enk activation of the K+ current was reported to be 1 μM
(Bailey et al. 2009). We next examined whether GSK1521498
exhibited inverse agonism atMOPr in CHO cells when the level
of expression was lower, at the level of endogenous MOPr
expression in the brain. We used membranes from CHO cells
that expressed MOPr at a level of approximately 70 fmol per
milligram of protein. In these membranes, GSK1521498, nal-
trexone, naloxone and 6-β-naltrexol (all at 1μM)did notmodify
the basal level of GTPγS binding (Fig. 3b). In contrast,
DAMGO (1 μM) still stimulated [35S]GTPγS binding by over
50 % in these membranes (data not shown).
To further examine whether GSK1521498 has inverse
agonist properties at MOPr, we examined its ability to reduce
[35S]GTPγS binding in membranes from mouse brain. It has
previously been reported that while the inverse agonist activ-
ity ofβ-CNA can be observed in brain membranes from naïve
mice, constitutive MOPr activity is enhanced by morphine
pre-treatment, and this reveals the inverse agonist activity of
other antagonists such as naltrexone and naloxone (Wang
et al. 2001, 2004).We compared the inverse agonist properties
of GSK1521498, β-CNA, naltrexone and 6-β-naltrexol in
membranes prepared from naïve mice and mice pretreated
with morphine. We used three morphine pre-treatments, as
described in the “Methods and materials”. These are charac-
terized as acute, moderate and severe morphine pre-treatments
(Raehal et al. 2005).
Basal [35S]GTPγS binding levels were the same in brain
membranes prepared from naïve mice and from mice receiv-
ing acute morphine, moderate morphine and severe morphine
pre-treatments (Table 3), i.e. morphine pre-treatment did not
enhance MOPr constitutive activity. Furthermore, we did not
observe any inhibition of basal [35S]GTPγS binding by β-
CNA (1 μM) or naltrexone (1 μM) in membranes from naïve
or morphine-treated animals (Fig. 4). We did, paradoxically,
Table 1 Antagonist potency (fpKi values) for the antagonists at opioid
receptors
MOPr DOPr KOPr NOPr
GSK1521498 9.64±0.06 8.50±0.03 8.48±0.14 6.59±0.13
Naloxone 8.68±0.14 7.51±0.16 7.50±0.16 <5
Naltrexone 9.15±0.13 8.26±0.10 8.78±0.07 <5
6β-Naltrexol 8.72±0.11 7.71±0.10 8.52±0.05 <5
Nalmefene 9.62±0.12 8.08±0.06 – <5
Data are presented as mean±SEM of three experiments
Psychopharmacology (2015) 232:305–314 309
observe a small increase in GTPγS binding with naltrexone in
membranes prepared from mice receiving moderate but not
acute or severe morphine pre-treatment. The lack of any
inverse agonist effect of β-CNA was surprising given
previous studies (Wang et al. 2001, 2004). We therefore
sought to demonstrate that the sample of β-CNA used did
bind to MOPr and functioned as an antagonist. β-CNA
displaced specific 3H-naloxone binding in membranes from
MOPr-HEK cells in a concentration-dependent manner and
prevented DAMGO stimulation of GTPγS binding in mouse
brain membranes (data not shown).
When tested at a concentration of 1 μM, GSK1521498 did
not reduce basal [35S]GTPγS binding to brain membranes
prepared from naïve, acute and moderate morphine-
pretreated animals (Fig. 4). Only in membranes from severe
morphine-pretreated animals did GSK1521498 show very
slight but statistically significant inhibition of basal
[35S]GTPγS binding (Fig. 4).
Table 2 Affinity of binding (pKi) of MOPr antagonists to MOPr





Data are presented as mean±SEM
Fig. 2 Displacement of
[3H]naloxone binding to MOPr.
a–c Competition displacement
binding curves for the
displacement of 3H-naloxone
binding by GSK1521498,
naltrexone, and 6-β-naltrexol to
membranes prepared from
HEK293 cells expressing the
human MOPr. d Kinetics of
[3H]naloxone dissociation from
MOPr in the absence and
presence of GSK1521498,
naltrexone and 6-β-naltrexol (all
at 1 μM). Mean t1/2 values for
[3H]naloxone dissociation in the
presence of each drug are given
with 95 % confidence limits
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Discussion
Using recombinant human opioid receptors, we observed
GSK1521498 to be a selective MOPr antagonist with some
14-fold selectivity for MOPr over both DOPr and KOPr and
100-fold selectivity for MOPr over NOPr. This relative selec-
tivity for MOPr, DOPr and KOPr is similar to that reported by
Ignar et al. (2011), but in the present study, the absolute
potency of GSK1521498 was some 10-fold higher at each
receptor type than previously reported. Compared to
Table 3 Basal [35S]GTPγS binding to membranes of mouse brain fol-
lowing various morphine treatments
[35S]GTPγS binding
Naive Morphine acute Morphine moderate Morphine severe
3,618±356 3,057±157 2,857±342 3,361±543
Values are expressed as counts per minute bound per tube and are shown
as means±SEM from 9–11 separate experiments in each case, performed
in triplicate or quadruplicate. The values were not significantly different,
one-way ANOVAwith Bonferroni post-test. The same amount of mem-
brane protein (10 μg/tube) was used in each case
a
b
Fig. 3 Effect of antagonists on
basal [35S]GTPγS binding to





naltrexone (white circle), 6-β-
naltrexol (black up-pointing
triangle) and nalmefene (white
square) in CHO cell membranes
overexpressing MOPr. Mean data
are expressed as percentage of the
basal binding, determined in the
absence of ligands. At
concentrations greater than
0.4 nM, GSK1521498 produced a
significant inhibition of basal
[35S]GTPγS binding (p<0.001,
ANOVA on log-transformed raw
data, with treatment and plates as
independent factors). b Drugs
were tested at a final
concentration of 1 μM on
membranes prepared from CHO
cells expressing a low level of
MOPr. Values are expressed as a
percentage of the basal value in
the absence of drug, which was
taken as 100 % in each
experiment. Values shown as
means±SEM from five separate
experiments in each case. None of
the drugs had a significant effect
on basal [35S]GTPγS binding
(one sample t test)
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naltrexone, GSK1521498 was more selective for MOPr and
had greater affinity for MOPr binding. We also observed that
whereas GSK1521498 could completely antagonize MOPr
activation by an exogenous agonist challenge, naltrexone,
naloxone and 6-β-naltrexol could achieve only about 70 %
blockade even at high doses.
Positive and negative allosteric modulation of G protein-
coupled receptors (GPCRs) has been widely reported (see
Keov et al. (2011) for review). Novel allosteric modulators
of MOPr have recently been described (Burford et al. 2013).
GSK1521498 is structurally unrelated to otherMOPr selective
antagonists. It was therefore important to determine whether
or not it acted at the same orthosteric binding site as classical
antagonists that have chemical structures based on the mor-
phine structure (Corbett et al. 2006). GSK1521498 displaced
all [3H]naloxone-specific binding to MOPr and did not alter
the rate of [3H]naloxone dissociation from MOPr. Both of
these observations are compatible with it acting at the same
orthosteric site as naloxone.
We and others (Ignar et al. 2011) have observed that
GSK1521498 exhibits inverse agonist activity on highly
overexpressed recombinant MOPr. Overexpression of recep-
tors is likely to facilitate the measurement of MOPr constitu-
tive activity thus revealing inverse agonist activity in drugs
otherwise thought to be neutral antagonists. We did not,
however, observe inverse agonist activity of GSK1521498
when the level of expression was lower either on recombinant
MOPr in CHO cells or on endogenous MOPr in mouse brain
tissue from control animals. In brain tissue from animals
receiving morphine pre-treatment of increasing severity, there
was a tendency for GSK1521498 to exhibit inverse agonist
activity, but this was slight and only achieved statistical sig-
nificance with the most severe morphine pre-treatment regi-
men. However, the slight inverse agonism of GSK1521498 at
high levels of receptor overexpression, or the highest dose of
morphine pre-treatment, was in contrast to the behaviour of
the other MOPr ligands in this assay. We did not observe
inverse agonist activity for β-CNA or naltrexone in brain
tissue from mice receiving any of the morphine pre-
treatments. This is in contrast to Wang et al. (2001, 2004)
who have observed inverse agonism activity for these com-
pounds on endogenous MOPr. In the studies of recombinant
human MOPr overexpressed in cell lines, we confirmed prior
data that naltrexone (Ignar et al. 2011) had partial agonist
activity, as did naloxone and the putative neutral antagonist
6-β-naltrexol. Recently, Bourassa et al. (2014) have also
reported that naloxone and naltrexone behave as partial ago-
nists at MOPr.
Opioid pre-treatment has been reported to increase MOPr
constitutive activity presumably by increasing the phosphor-
ylation state of MOPr (Liu et al. 2001; Sally et al. 2010; Wang
et al. 2004, 2007; Xu et al. 2007 but see Divin et al. 2009). We
did not observe any increase in basal GTPγS binding in
mouse brain homogenates following any of the morphine
pre-treatments. In our brain membrane experiments, the assay
buffer contained Na+ which may reduce the level of constitu-
tive G-protein signalling (Liu et al. 2001; Szekeres and
Traynor 1997), but we used conditions identical to those of
Wang et al. (2004) who had previously observed MOPr con-
stitutive activity. Selley et al. (1997) have also failed to ob-
serve any increase in MOPr constitutive activity following
morphine pre-treatment. While the reasons for this discrepan-
cy are unknown, there might be subtle methodological factors
that may be relevant. For example, it has been pointed out that
in chronic opioid-pre-treatment studies, it is essential to ensure
that all of the pre-treating agonist has been removed from
tissue before evaluating constitutive activity and potential
inverse agonists (Williams et al. 2013). We conclude that the
Fig. 4 Effect of antagonists on basal [35S]GTPγS binding to membranes
from whole mouse brain, following different morphine pre-treatments.
Drugs were tested at a final concentration of 1 μM. Values are expressed
as a percentage of the basal value in the absence of antagonist drug, which
was taken as 100 % in each experiment. Values shown as means±SEM
from five to six separate experiments in each case, each performed in
triplicate or quadruplicate.*p<0.05 compared to 100 %, one-sample t test
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inverse agonist action of GSK1521498 is not simply revealed
by an elevated level of MOPr constitutive activity following
chronic morphine treatment but results from some other as yet
unidentified modification of MOPr function.
Functional studies in neurons and cell lines under physio-
logical conditions have failed to detect MOPr constitutive
activity after chronic morphine exposure in locus coeruleus
neurons (Connor et al. 1999), periaqueductal gray neurons
(Bagley et al. 2005) or SH-SY5Y cells (Kennedy and
Henderson 1992). Indeed, the ability of other GPCRs to
exhibit constitutive activity can be cell context-dependent,
with for example, group I mGluRs showing extensive consti-
tutive activity in expression systems but not in neurons, the
reason for the latter being that in brain the receptor interacts
with Homer proteins that suppress constitutive activity (Ango
et al. 2001). More recently, MOPr constitutive activity and
inverse agonist activity of naloxone and naltrexone were
observed in dorsal root ganglion neurons cultured from
βarrestin2 knockout but not wild-type mice (Lam et al.
2011; Walwyn et al. 2007).
The issue of whether MOPrs exhibit constitutive activity
and whether some antagonists are actually inverse agonists
remains confusing with different results being observed by
different groups using apparently similar experimental proce-
dures (see Connor and Traynor 2010). The present results
indicate that whilst GSK1521498 could exhibit inverse ago-
nist activity under conditions where MOPr are highly
overexpressed, but not at lower level of expression of recom-
binant receptors or at untreated endogenous MOPrs, the other
ligands examined (naloxone, naltrexone and 6-β-naltrexol)
did not show any inverse agonist activity but instead under
conditions of high receptor expression, displayed partial ago-
nist activity.
Finally, we return to the question of how these pharmaco-
logical differences between GSK1521498 and other MOPr
ligands could be related to the previously reported behavioural
differences between GSK1521498 and naltrexone (Giuliano
et al. 2013). In this prior study, both GSK1521498 and nal-
trexone inhibited drug-seeking behaviour for cocaine or her-
oin in a second-order reinforcement paradigm, but this effect
was significantly greater for GSK1521498 compared to an
equivalent dose of naltrexone. Moreover, GSK1521498
inhibited further drug-seeking behaviour after a first self-
administration of heroin, which naltrexone did not. There are
many possible pharmacological reasons for the apparently
greater efficacy of GSK152498 to modulate behaviour in
these rodent models of drug dependence. As previously
shown, and confirmed independently here, GSK1521498 is
more selective for the mu opioid receptor, which is theoreti-
cally implicated in reward signalling. It is also conceivable
that the more complete antagonism achieved by
GSK1521498, and its slight inverse agonist activity under
some assay conditions, compared to the incomplete
antagonism and partial agonist activity of naltrexone (and
the other opioid receptor ligands studied), might contribute
to its different behavioural profile, by more completely atten-
uating MOPr-mediated signalling in brain centres controlling
reward-driven behaviour. However, we note that the inverse
agonist activity of GSK1521498 was only demonstrated un-
der conditions of high receptor expression in vitro or in mice
pre-treated with the highest dose of morphine. It is debatable
to what extent these assay conditions are typical of normal
physiological or pathophysiological states of the MOPr
system.
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